Lupin expands U.S. footprint with new Bridgewater corporate offices

Lupin Limited announced the inauguration of its new corporate offices at 100 Somerset Corporate Blvd in Bridgewater, New Jersey, on October 28, 2025. This expansion strengthens Lupin's presence in the state, which already includes manufacturing and research facilities in Somerset. The new approximately 18,000 square foot office will accommodate various corporate functions, including commercial, HR, finance, legal, marketing, business development, and R&D. Governor Phil Murphy and Somerset County Commissioner Deputy Director Melonie Marano attended the ribbon-cutting ceremony alongside Lupin executives, including chief executive vinita gupta, president of U.S. generics spiro gavaris, and chief technical operations officer christoph funke.

New Jersey Governor Phil Murphy highlighted that Lupin’s continued investments align with the state’s priorities of strengthening the pharmaceutical industry, driving economic growth, and creating skilled jobs. Vinita Gupta emphasized that the state’s operations, including corporate offices, manufacturing, and research facilities, are crucial to the company's U.S. growth and expansion, enabling innovation and access to affordable medications.

Spiro Gavaris, president of U.S. generics, Lupin, noted that increasing the company's presence in New Jersey allows it to scale operations, grow its workforce, and contribute to the community. The NJ-based workforce currently exceeds 300 employees, with plans for continued growth, leveraging the state's robust talent pool in the life sciences sector. Lupin operates 15 manufacturing sites and 7 research centers globally, and employs over 24,000 professionals.